Adult AIDS-like disease in a novel inducible human immunodeficiency virus type 1 Nef transgenic mouse model: CD4+ T-cell activation is Nef dependent and can occur in the absence of lymphophenia

Journal of Virology

Volumn 83, Issue 22, 2009, Pages 11830-11846

  Rahim, Mir Munir Ahmed ^a   Chrobak, Pavel ^a   Hu, Chunyan ^a   Hanna, Zaher ^a,b,c   Jolicoeur, Paul ^a,b,c  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; NEF PROTEIN; TETRACYCLINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CHIMERA; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HEMATOPOIETIC CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LYMPHOCYTOPENIA; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TRANSGENE; TRANSGENIC MOUSE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; APOPTOSIS; BLOTTING, NORTHERN; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; HIV-1; LYMPHOCYTE ACTIVATION; MICE; MICE, TRANSGENIC; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PHENOTYPE;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS; MUS MUSCULUS;

EID: 70350330462     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01466-09     Document Type: Article

References (53)

1. Bourgeois, C., Z. Hao, K. Rajewsky, A. J. Potocnik, and B. Stockinger. 2008. Ablation of thymic export causes accelerated decay of naive CD4 T cells in the periphery because of activation by environmental antigen. Proc. Natl. Acad. Sci. USA 105:8691-8696.
2. Brady, H. J., D. J. Abraham, D. J. Pennington, C. G. Miles, S. Jenkins, and E. A. Dzierzak. 1995. Altered cytokine expression in T lymphocytes from human immunodeficiency virus Tat transgenic mice. J. Virol. 69:7622-7629.
3. Brady, H. J., D. J. Pennington, C. G. Miles, and E. A. Dzierzak. 1993. CD4 cell surface downregulation in HIV-1 Nef transgenic mice is a consequence of intracellular sequestration. EMBO J. 12:4923-4932. (Pubitemid 23358481)
4. Brenchley, J. M., D. A. Price, T. W. Schacker, T. E. Asher, G. Silvestri, S. Rao, Z. Kazzaz, E. Bornstein, O. Lambotte, D. Altmann, B. R. Blazar, B. Rodriguez, L. Teixeira-Johnson, A. Landay, J. N. Martin, F. M. Hecht, L. J. Picker, M. M. Lederman, S. G. Deeks, and D. C. Douek. 2006. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12:1365-1371.
5. Bronson, S. K., E. G. Plaehn, K. D. Kluckman, J. R. Hagaman, N. Maeda, and O. Smithies. 1996. Single-copy transgenic mice with chosen-site integration. Proc. Natl. Acad. Sci. USA 93:9067-9072.
6. Cochrane, A., S. Imlach, C. Leen, G. Scott, D. Kennedy, and P. Simmonds. 2004. High levels of human immunodeficiency virus infection of CD8 lymphocytes expressing CD4 in vivo. J. Virol. 78:9862-9871. (Pubitemid 39187106)
7. Cullen, B. R. 2001. A new entry route for HIV. Nat. Med. 7:20-21.
8. Dickie, P. 2000. Nef modulation of HIV type 1 gene expression and cytopathicity in tissues of HIV transgenic mice. AIDS Res. Hum. Retrovir. 16:777-790.
9. Dickie, P., F. Ramsdell, A. L. Notkins, and S. Venkatesan. 1993. Spontaneous and inducible epidermal hyperplasia in transgenic mice expressing HIV-1 Nef. Virology 197:431-438. (Pubitemid 23313574)
10. Djordjevic, J. T., S. D. Schibeci, G. J. Stewart, and P. Williamson. 2004. HIV type 1 Nef increases the association of T cell receptor (TCR)-signaling molecules with T cell rafts and promotes activation-induced raft fusion. AIDS Res. Hum. Retrovir. 20:547-555.
11. Fahey, J. L., J. M. Taylor, B. Manna, P. Nishanian, N. Aziz, J. V. Giorgi, and R. Detels. 1998. Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements. AIDS 12:1581-1590.
12. Fenard, D., W. Yonemoto, C. De Noronha, M. Cavrois, S. A. Williams, and W. C. Greene. 2005. Nef is physically recruited into the immunological synapse and potentiates T cell activation early after TCR engagement. J. Immunol. 175:6050-6057. (Pubitemid 41508091)
13. Furth, P. A., L. St Onge, H. Boger, P. Gruss, M. Gossen, A. Kistner, and H. L. Bujard. 1994. Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. Proc. Natl. Acad. Sci. USA 91:9302-9306.
14. Giorgi, J. V., L. E. Hultin, J. A. McKeating, T. D. Johnson, B. Owens, L. P. Jacobson, R. Shih, J. Lewis, D. J. Wiley, J. P. Phair, S. M. Wolinsky, and R. Detels. 1999. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J. Infect. Dis. 179:859-870.
15. Gossen, M., S. Freundlieb, G. Bender, G. Muller, W. Hillen, and H. Bujard. 1995. Transcriptional activation by tetracyclines in mammalian cells. Science 268:1766-1769.
16. Goudreau, G., S. Carpenter, N. Beaulieu, and P. Jolicoeur. 1996. Vacuolar myelopathy in transgenic mice expressing human immunodefiency virus type 1 proteins under the regulation of the myelin basic protein gene promoter. Nat. Med. 2:655-661.
17. Hanna, Z., D. G. Kay, M. Cool, S. Jothy, N. Rebai, and P. Jolicoeur. 1998. Transgenic mice expressing human immunodeficiency virus type 1 in immune cells develop a severe AIDS-like disease. J. Virol. 72:121-132. (Pubitemid 28048820)
18. Hanna, Z., D. G. Kay, N. Rebai, A. Guimond, S. Jothy, and P. Jolicoeur. 1998. Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice. Cell 95:163-175. (Pubitemid 28473778)
19. Hanna, Z., E. Priceputu, P. Chrobak, C. Hu, V. Dugas, M. Goupil, M. Marquis, L. de Repentigny, and P. Jolicoeur. 2009. Selective expression of human immunodeficiency virus Nef in specific immune cell populations of transgenic mice is associated with distinct AIDS-like phenotypes. J. Virol. 83:9743-9758.
20. Hanna, Z., E. Priceputu, C. Hu, P. Vincent, and P. Jolicoeur. 2006. HIV-1 Nef mutations abrogating downregulation of CD4 affect other Nef functions and show reduced pathogenicity in transgenic mice. Virology 346:40-52. (Pubitemid 43254698)
21. Hanna, Z., N. Rebai, J. Poudrier, and P. Jolicoeur. 2001. Distinct regulatory elements are required for faithful expression of human CD4 in T-cells, macrophages and dendritic cells of transgenic mice. Blood 98:2275-2278.
22. + T cells and in macrophages of transgenic mice. Mol. Cell. Biol. 14:1084-1094.
23. Hazenberg, M. D., S. A. Otto, B. H. van Benthem, M. T. Roos, R. A. Coutinho, J. M. Lange, D. Hamann, M. Prins, and F. Miedema. 2003. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 17:1881-1888.
24. Iwakura, Y., T. Shioda, M. Tosu, E. Yoshida, M. Hayashi, T. Nagata, and H. Shibuta. 1992. The induction of cataracts by HIV-1 in transgenic mice. AIDS 6:1069-1075.
25. Kistner, A., M. Gossen, F. Zimmermann, J. Jerecic, C. Ullmer, H. Lubbert, and H. Bujard. 1996. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc. Natl. Acad. Sci. USA 93:10933-10938.
26. Koenen, P. G., F. M. Hofhuis, M. A. Oosterwegel, and K. Tesselaar. 2007. T cell activation and proliferation characteristic for HIV-Nef transgenic mice is lymphopenia induced. J. Immunol. 178:5762-5768.
27. Kopp, J. B., M. E. Klotman, S. H. Adler, L. A. Bruggeman, P. Dickie, N. J. Marinos, M. Eckhaus, J. L. Bryant, A. L. Notkins, and P. E. Klotman. 1992. Progressive glomerulosclerosis and enhanced renal accumulation of basement membrane components in mice transgenic for human immunodeficiency virus type 1 genes. Proc. Natl. Acad. Sci. USA 89:1577-1581.
28. Kourtis, A. P., C. Ibegbu, A. J. Nahmias, F. K. Lee, W. S. Clark, M. K. Sawyer, and S. Nesheim. 1996. Early progression of disease in HIV-infected infants with thymus dysfunction. N. Engl. J. Med. 335:1431-1436.
29. Leonard, J. M., J. W. Abramczuk, D. S. Pezen, R. Rutledge, J. H. Belcher, F. S. G. Hakim, L. Lamperth, W. Travis, T. Fredrickson, et al. 1988. Development of disease and virus recovery in transgenic mice containing HIV proviral DNA. Science 242:1665-1670.
30. Lindemann, D., R. Wilhelm, P. Renard, A. Althage, R. Zinkernagel, and J. Mous. 1994. Severe immunodeficiency associated with a human immunodeficiency virus 1 NEF/3′-long terminal repeat transgene. J. Exp. Med. 179:797-807.
31. Livingstone, W. J., M. Moore, D. Innes, J. E. Bell, P. Simmonds, et al. 1996. Frequent infection of peripheral blood CD8-positive T- lymphocytes with HIV-1. Lancet 348:649-654. (Pubitemid 26293810)
32. Oswald-Richter, K., S. M. Grill, N. Shariat, M. Leelawong, M. S. Sundrud, D. W. Haas, and D. Unutmaz. 2004. HIV infection of naturally occurring and genetically reprogrammed human regulatory T-cells. PLoS Biol. 2:E198. (Pubitemid 39234409)
33. Pennington, D. J., S. A. Jenkins, H. J. Brady, C. G. Miles, E. A. Dzierzak, and D. J. Abraham. 1997. HIV- I Nef severely impairs thymocyte development and peripheral T-cell function by a CD4-independent mechanism. Genes Funct. 1:321-335.
34. Plum, J., M. De Smedt, G. Leclercq, T. Taghon, T. Kerre, and B. Vandekerckhove. 2008. Human intrathymic development: a selective approach. Semin. Immunopathol. 30:411-423.
35. Popov, J., T. McGraw, B. Hofmann, B. Vowels, A. Shum, P. Nishanian, and J. L. Fahey. 1992. Acute lymphoid changes and ongoing immune activation in SIV infection. J. Acquir. Immune Defic. Syndr. 5:391-399.
36. Priceputu, E., Z. Hanna, C. Hu, M.-C. Simard, P. Vincent, S. Wildum, M. Schindler, F. Kirchhoff, and P. Jolicoeur. 2007. Primary human immunodeficiency virus type 1 Nef alleles show major differences in pathogenicity in transgenic mice. J. Virol. 81:4677-4693. (Pubitemid 46668665)
37. Priceputu, E., I. Rodrigue, P. Chrobak, J. Poudrier, T. W. Mak, Z. Hanna, Hu.C., D. G. Kay, and P. Jolicoeur. 2005. The Nef-mediated AIDS-like disease of CD4C/HIV transgenic mice is associated with increased Fas/FasL expression on T cells and T cell death, but is not prevented in Fas, FasL, TNFR-1 and ICE deficient nor in Bcl2-expressing transgenic mice. J. Virol. 79:6377-6391.
38. Radja, F., D. G. Kay, S. Albrecht, and P. Jolicoeur. 2003. Oligodendrocyte-specific expression of human immunodeficiency virus type 1 Nef in transgenic mice leads to vacuolar myelopathy and alters oligodendrocyte phenotype in vitro. J. Virol. 77:11745-11753.
39. Rothenberg, E. V., and T. Taghon. 2005. Molecular genetics of T cell development. Annu. Rev. Immunol. 23:601-649.
40. + T cells in patients with AIDS: implications for HIV-1 pathogenesis. J. Acquir. Immune Defic. Syndr. 26:199-207.
41. Silvestri, G., D. L. Sodora, R. A. Koup, M. Paiardini, S. P. O'Neil, H. M. McClure, S. I. Staprans, and M. B. Feinberg. 2003. Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity 18:441-452. (Pubitemid 36351522)
42. Simard, M.-C., P. Chrobak, D. G. Kay, Z. Hanna, S. Jothy, and P. Jolicoeur. 2002. Expression of simian immunodeficiency virus Nef in immune cells of transgenic mice leads to a severe AIDS-like disease. J. Virol. 76:3981-3995. (Pubitemid 34250563)
43. Simmons, A., V. Aluvihare, and A. McMichael. 2001. Nef triggers a transcriptional program in T cells imitating single-signal T cell activation and inducing HIV virulence mediators. Immunity 14:763-777. (Pubitemid 32592423)
44. Skowronski, J., D. Parks, and R. Mariani. 1993. Altered T cell activation and development in transgenic mice expressing the HIV-1 nef gene. EMBO J. 12:703-713. (Pubitemid 23073718)
45. Tinkle, B. T., L. Ngo, P. A. Luciw, T. Maciag, and G. Jay. 1997. Human immunodeficiency virus-associated vasculopathy in transgenic mice. J. Virol. 71:4809-4814. (Pubitemid 27204175)
46. Toggas, S. M., E. Masliah, E. M. Rockenstein, G. F. Rall, C. R. Abraham, and L. Mucke. 1994. Central nervous system damage produced by expression of the HIV- 1 coat protein gp120 in transgenic mice. Nature 367:188-193.
47. Tumbar, T., G. Guasch, V. Greco, C. Blanpain, W. E. Lowry, M. Rendl, and E. Fuchs. 2004. Defining the epithelial stem cell niche in skin. Science 303:359-363. (Pubitemid 38095773)
48. Urlinger, S., U. Baron, M. Thellmann, M. T. Hasan, H. Bujard, and W. Hillen. 2000. Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc. Natl. Acad. Sci. USA 97:7963-7968.
49. Vellutini, C., N. Horschowski, V. Philippon, D. Gambarelli, and K. A. F. P. Nave. 1995. Development of lymphoid hyperplasia in transgenic mice expressing the HIV tat gene. AIDS Res. Hum. Retrovir. 11:21-29.
50. Vincent, P., E. Priceputu, D. Kay, K. Saksela, P. Jolicoeur, and Z. Hanna. 2006. Activation of p21-activated kinase 2 and its association with Nef are conserved in murine cells but are not sufficient to induce an AIDS-like disease in CD4C/HIV transgenic mice. J. Biol. Chem. 281:6940-6954.
51. Vogel, J., S. H. Hinrichs, L. A. Napolitano, L. Ngo, and G. Jay. 1991. Liver cancer in transgenic mice carrying the human immunodeficiency virus tat gene. Cancer Res. 51:6686-6690.
52. Vogel, J., S. H. Hinrichs, R. K. Reynolds, P. A. Luciw, and G. Jay. 1988. The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice. Nature 335:606-611. (Pubitemid 18237570)
53. Weng, X., E. Priceputu, P. Chrobak, J. Poudrier, D. G. Kay, Z. Hanna, T. W. Mak, and P. Jolicoeur. 2004. CD4 T cells from CD4C/HIV nef transgenic mice show enhanced activation in vivo with impaired proliferation in vitro, but are dispensable for the development of a severe AIDS-like organ disease. J. Virol. 78:5244-5257. (Pubitemid 38581476)